Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients

Fahrettin Covut, MD, Ramsha Ahmed, MD, Christy J. Samaras, DO, Faiz Anwer, MD, Alex V. Mejia Garcia, MD, Dana E Angelini, MD, Beth M. Faiman, PhDCNP, Janice Reed, RN, Mary Ann Karam, RN, Kristen Schlueter, RN, Saveta Mathur, CNP, Kimberly Hamilton, APRN/PA, Nathaniel Rosko, PharmD, Jason Valent, MD, Jack Khouri, MD

Blood (2019) 134 (Supplement_1): 3148.

https://doi.org/10.1182/blood-2019-131400

Published: 2019

Journal Articles

Reversal of Apixaban Anticoagulation with Reduced Doses of Andexanet Alfa in a Porcine Polytrauma Model

Oliver Grottke, MD PhD MPH, Necib Akman, MD, Till Braunschweig, MD, Pamela B. Conley, PhD, Rolf Rossaint, MD

Blood (2018) 132 (Supplement 1): 2456.

https://doi.org/10.1182/blood-2018-99-114426

Published: 2018

Journal Articles

The Impact of Fractures on Survival in Multiple Myeloma: Results from a Population-Based Study

Sigrun Thorsteinsdottir, MD, Ingigerdur S Sverrisdottir, MD, Gauti Gislason, MSc, Ola Landgren, MD PhD, Ingemar Turesson, MD PhD, Magnus Björkholm, MD PhD, Sigurdur Y Kristinsson, MD PhD

Blood (2018) 132 (Supplement 1): 4490.

https://doi.org/10.1182/blood-2018-99-115403

Published: 2018

Journal Articles

Good Care and Long-Term Follow-up in Young Hemophiliacs

Zeynep Iscan, MD, Basak Koc, MD, Onder Kilicoglu, Prof, Ata Atalar, Prof, Omer Taser, Prof, Gulten Cetik, Bulent Zulfikar, Prof

Blood (2018) 132 (Supplement 1): 5028.

https://doi.org/10.1182/blood-2018-99-117936

Published: 2018

Journal Articles

Comparison of Second and First Generation of Andexanet Alfa in a Porcine Polytrauma Model with Apixaban Anticoagulation

Oliver Grottke, MD PhD MPH, Necib Akman, MD, Till Braunschweig, MD, Pamela B. Conley, PhD, Rolf Rossaint, MD

Blood (2018) 132 (Supplement 1): 3778.

https://doi.org/10.1182/blood-2018-99-114542

Published: 2018

Journal Articles

The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials

M. Judith Peterschmitt, MD, Selena Freisens, MD, Audrey W Hou, PharmD, Lisa Underhill, MS, Meredith C. Foster, ScD, Sebastiaan J.M. Gaemers, MD

Blood (2018) 132 (Supplement 1): 3692.

https://doi.org/10.1182/blood-2018-99-118319

Published: 2018

Journal Articles

Management of Joint Replacement in Hemophilia a with Inhibitors during Emicizumab Prophylaxis

Elena Santagostino, Maria Elisa Mancuso, MD PhD, Cristina Novembrino, Massimo Anzoletti Boscolo, Marigrazia Clerici, Gianluigi Pasta, MD, Luigi Piero Solimeno, MD, Flora Peyvandi

Blood (2017) 130 (Supplement 1): 2360.

https://doi.org/10.1182/blood.V130.Suppl_1.2360.2360

Published: 2017

Journal Articles

Blood Loss in Rivaroxaban Anticoagulated Pigs with Severe Polytrauma Is Significantly Reduced By Early Therapy with Prothrombin Complex Concentrate

Oliver Grottke, MD PhD MPH, Necib Akman, MD, Till Braunschweig, MD, Markus Honickel, MD, Hugo ten Cate, MD PhD

Blood (2017) 130 (Supplement 1): 2392.

https://doi.org/10.1182/blood.V130.Suppl_1.2392.2392

Published: 2017

Journal Articles

Markers of Thromboembolic Risk Were Insignificantly Affected By Either Intraosseous or Intravenous Idarucizumab in a Dabigatran-Anticoagulated Porcine Polytrauma Model

Markus Honickel, MD, Akman Necib, MD, Hugo ten Cate, MD PhD, Rolf Rossaint, MD Prof, Oliver Grottke, MD PhD

Blood (2016) 128 (22): 2623.

https://doi.org/10.1182/blood.V128.22.2623.2623

Published: 2016

Journal Articles

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Hervé Tilly, MD PhD, Franck Morschhauser, Nancy L Bartlett, MD, Jeff Sharman, MD, Corinne Haioun, MD PhD, Kathryn S. Kolibaba, Andy Chen, DO, Thierry Lamy, MD PhD, Surai Jones, MS Biostat, Elicia Penuel, PhD, Calvin Lee, Gilles A. Salles

Blood (2016) 128 (22): 1853.

https://doi.org/10.1182/blood.V128.22.1853.1853

Published: 2016

Journal Articles

Increased Fracture Risk in Patients with Untreated Chronic Lymphocytic Leukemia (CLL): A Population-Based Analysis

Adam J Olszewski, MD, Roee Gutman, PhD, Charles B Eaton, MD MS

Blood (2015) 126 (23): 878.

https://doi.org/10.1182/blood.V126.23.878.878

Published: 2015

Journal Articles

Mechanistic Differences of Prothrombin Complex Concentrate and Idarucizumab in a Trauma Model Under Dabigatran Anticoagulation

Markus Honickel, MD, Joanne van Ryn, PhD, Oliver Grottke, MDPhD

Blood (2015) 126 (23): 1128.

https://doi.org/10.1182/blood.V126.23.1128.1128

Published: 2015

Journal Articles

Prothrombin Complex Concentrate or Idarucizumab in a Multimodal Hemostatic Approach with Tranexamic Acid and Fibrinogen for the Acute Reversal of Dabigatran

Oliver Grottke, MDPhD, Markus Honickel, MD, Rolf Rossaint, MDProf, Till Braunschweig, MD

Blood (2015) 126 (23): 2275.

https://doi.org/10.1182/blood.V126.23.2275.2275

Published: 2015

Journal Articles

FEIBA™ for Patients on Direct Oral Anticoagulants Requiring Urgent Surgery

Joseph Shaw, B.Sc, Gregoire Le Gal, MDPhD, Melanie Tokessy, Nancy Cober, Elianna Saidenberg, MD, Marc Carrier, MDMSc, Lana Castellucci, MDMSc

Blood (2014) 124 (21): 4259.

https://doi.org/10.1182/blood.V124.21.4259.4259

Published: 2014

Journal Articles

Current Practice Patterns of Phamacological Thromboprophylaxis for Prevention of Venous Thromboembolism in Hospitalized Children: A Survey of Pediatric Hemostasis and Thrombosis Experts in North America

Sherif M Badawy, MD, Anjali Sharathkumar, MDMS

Blood (2014) 124 (21): 4274.

https://doi.org/10.1182/blood.V124.21.4274.4274

Published: 2014

Journal Articles

Efficacy and Safety of Bortezomib Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in Japanese Patients (Pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL) Not Considered for Transplantation Enrolled in the International, Randomized, Phase 3 LYM-3002 Study (NCT00722137)

Michinori Ogura, MD PhD, Lixia Pei, PhD, Brendan Rooney, PhD, Helgi van de Velde, MD PhD, Franco Cavalli, MD for the LYM-3002 investigators

Blood (2014) 124 (21): 3061.

https://doi.org/10.1182/blood.V124.21.3061.3061

Published: 2014

Journal Articles

Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Raymond Perez, MD, Rachid Baz, MD, Paul G. Richardson, Kenneth C. Anderson, MD, Peter Sabbatini, PhD, Clifford Dilea, Pina M. Cardarelli, PhD, Mark Wade, Guan Xing, PhD, Andres Gutierrez, MD PhD, Lewis Cohen, MD MS, Pamela S. Becker, MD PhD

Blood (2014) 124 (21): 3483.

https://doi.org/10.1182/blood.V124.21.3483.3483

Published: 2014

Journal Articles

Prothrombin Complex Concentrate in Combination with Fibrinogen Plus Tranexamic Acid Is More Effective Than Mono-Therapy with Prothrombin Complex Concentrate in a Dabigatran Anticoagulation Experimental Polytrauma Model

Oliver Grottke, MD PhD, Markus Honickel, MD, Henri M.H. Spronk, PhD, Hugo ten Cate, Joanne van Ryn, PhD, Rolf Rossaint, MD

Blood (2014) 124 (21): 346.

https://doi.org/10.1182/blood.V124.21.346.346

Published: 2014

Journal Articles

Chronic Myeloproliferative Neoplasms and Risk of Osteoporosis. A Nationwide Population-Based Cohort Study.

Sarah Farmer, Erzsebet Horváth-Puhó, Hanne Vestergaard, MD, Henrik Frederiksen, Pernille Hermann, Henrik Toft Sørensen

Blood (2012) 120 (21): 2835.

https://doi.org/10.1182/blood.V120.21.2835.2835

Published: 2012

Journal Articles

Deficiency in Plasminogen Cause Decreased Vascularity in Sold Tissue Organs and Bone

Nicholas Mignemi, Heather Cole, Masato Yausa, M.D., David Gailani, MD, Jay L. Degen, PhD, Jonathan G Schoenecker, MD PhD

Blood (2011) 118 (21): 857.

https://doi.org/10.1182/blood.V118.21.857.857

Published: 2011

NARROW

External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients

Reversal of Apixaban Anticoagulation with Reduced Doses of Andexanet Alfa in a Porcine Polytrauma Model

The Impact of Fractures on Survival in Multiple Myeloma: Results from a Population-Based Study

Good Care and Long-Term Follow-up in Young Hemophiliacs

Comparison of Second and First Generation of Andexanet Alfa in a Porcine Polytrauma Model with Apixaban Anticoagulation

The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials

Management of Joint Replacement in Hemophilia a with Inhibitors during Emicizumab Prophylaxis

Blood Loss in Rivaroxaban Anticoagulated Pigs with Severe Polytrauma Is Significantly Reduced By Early Therapy with Prothrombin Complex Concentrate

Markers of Thromboembolic Risk Were Insignificantly Affected By Either Intraosseous or Intravenous Idarucizumab in a Dabigatran-Anticoagulated Porcine Polytrauma Model

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Increased Fracture Risk in Patients with Untreated Chronic Lymphocytic Leukemia (CLL): A Population-Based Analysis

Mechanistic Differences of Prothrombin Complex Concentrate and Idarucizumab in a Trauma Model Under Dabigatran Anticoagulation

Prothrombin Complex Concentrate or Idarucizumab in a Multimodal Hemostatic Approach with Tranexamic Acid and Fibrinogen for the Acute Reversal of Dabigatran

FEIBA™ for Patients on Direct Oral Anticoagulants Requiring Urgent Surgery

Current Practice Patterns of Phamacological Thromboprophylaxis for Prevention of Venous Thromboembolism in Hospitalized Children: A Survey of Pediatric Hemostasis and Thrombosis Experts in North America

Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Prothrombin Complex Concentrate in Combination with Fibrinogen Plus Tranexamic Acid Is More Effective Than Mono-Therapy with Prothrombin Complex Concentrate in a Dabigatran Anticoagulation Experimental Polytrauma Model

Chronic Myeloproliferative Neoplasms and Risk of Osteoporosis. A Nationwide Population-Based Cohort Study.

Deficiency in Plasminogen Cause Decreased Vascularity in Sold Tissue Organs and Bone

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only